NASDAQ:XBIO Xenetic Biosciences Q3 2025 Earnings Report $2.21 +0.09 (+4.25%) Closing price 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Xenetic Biosciences EPS ResultsActual EPS-$0.33Consensus EPS -$0.49Beat/MissBeat by +$0.16One Year Ago EPSN/AXenetic Biosciences Revenue ResultsActual Revenue$1.03 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AXenetic Biosciences Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time8:30AM ETUpcoming EarningsXenetic Biosciences' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Xenetic Biosciences Earnings HeadlinesReviewing Allarity Therapeutics (NASDAQ:ALLR) & Xenetic Biosciences (NASDAQ:XBIO)September 27, 2026 | americanbankingnews.comXenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused PipelineSeptember 17, 2026 | rttnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 7 at 1:00 AM | Altimetry (Ad)Xenetic Biosciences y Santersus AG acuerdan crear un líder global en terapias contra las NETSeptember 16, 2026 | es.finance.yahoo.comXenetic Biosciences announces all-stock merger with Santersus, leaving existing shareholders with 15% stakeSeptember 16, 2026 | msn.comXenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks TranscriptSeptember 16, 2026 | seekingalpha.comSee More Xenetic Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email. Email Address About Xenetic BiosciencesXenetic Biosciences (NASDAQ:XBIO) is a clinical-stage biotechnology company focused on developing targeted therapeutics for cancer and other serious diseases. The company’s research and development activities center on immuno-oncology, cell therapy, and proprietary drug-development technologies intended to improve the effectiveness, safety, or delivery of existing and emerging treatments. Xenetic’s technology portfolio has included XCART, an investigational personalized cell-therapy platform designed to use a patient’s own immune cells to target tumor-associated antigens. The company has also advanced oncology drug candidates and related research programs, including XBIO-101, an investigational compound studied for potential use in cancer treatment. These programs remain subject to clinical testing and regulatory review. Based in the United States, Xenetic Biosciences has historically pursued development through internal research, clinical programs, and collaborations with biotechnology and pharmaceutical organizations. Its products are investigational and are not broadly marketed or approved for commercial use unless otherwise authorized by applicable regulators.View Xenetic Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
